September 18, 2026
The melanoma vaccine that drove a 137% month faces its next test in Madrid on October 23. Here is how to structure a defined-risk position into that event.
MRNA tacked on another 6% Thursday with no filing, no trial result, and no analyst action to explain it. As of September 17, Moderna closed at about $158.07, up from a previous close of $145.62. That is momentum trading a memory, which is fine until the next hard data point arrives and the market has to decide whether the memory was accurate.
Your Power Bill Is Funding the AI Boom
The bulk order that keeps the lights on across 13 states just jumped from $2.2 billion to $14.7 billion – nearly 7x in one year – because data centers are draining the grid. There’s one energy source that runs 24/7 with no fuel, and Washington just preserved its tax credits through 2033 while terminating everyone else’s. Google signed for 15 years. Bill Gates invested $100 million. One company has spent sixty years building it.
That data point has a date: October 23.
The ESMO Congress 2026 runs from October 23 to 27 in Madrid at IFEMA Madrid, one of the most influential annual gatherings in oncology worldwide. Moderna and Merck have already signaled they will present full INTerpath-001 efficacy data at an upcoming international medical meeting. The companies said they plan to present detailed INTerpath-001 data at an upcoming international medical meeting and engage with regulatory authorities regarding filing submissions for intismeran in combination with pembrolizumab. ESMO is the obvious venue, and the market is already pricing for it.
What the Science Actually Says
The thesis rests on two layers of data. At five-year follow-up in the Phase 2b KEYNOTE-942 study, intismeran autogene combined with Keytruda reduced the risk of recurrence or death by 49% compared to Keytruda alone, with a hazard ratio of 0.510. That result, presented at ASCO in June, hardened the investment case heading into Phase 3.
Central Banks Are Buying Gold at a Historic Pace
Central banks are quietly stockpiling gold… and reducing their dependence on the U.S. dollar. That raises an important question: what are they preparing for? The reason is worth understanding for your retirement savings. America’s Gold Company breaks down the trend in a free, no-pressure guide, including how precious metals can diversify your retirement.
Then on August 19, the confirmation came. The INTerpath-001 Phase 3 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, representing what the companies described as the first positive Phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer therapy. Critically, the companies have not yet released detailed efficacy or safety results from the Phase 3 trial. That is the gap ESMO closes. The market has been buying the Phase 3 headline for a month; Madrid is where it sees the numbers.
Wall Street’s collective reaction on August 19 amounted to roughly $92 billion in combined gains, signaling the street believes intismeran will become a pillar of melanoma care. Whether a $152 stock already reflects that belief is the question every trader needs to answer before taking a position.
The Options Landscape
Moderna’s 30-day implied volatility stood at about 79 on September 17, against a 52-week range of roughly 57 to 138. That places current IV closer to the low end of its post-catalyst range, which matters: the stock spent several sessions above 110 IV immediately following the August 19 announcement, and it has since compressed as the momentum trade matured. Entering here, the options buyer is not paying peak fear.
The call-to-put ratio on September 17 ran roughly 3-to-1 in favor of calls, with notable spreader activity in the September 25 weekly 157.50 and 165 strikes as the stock moved up 10.5%. Institutional positioning is leaning directionally bullish into the ESMO window.
Inside the Nuclear Revival Reshaping Energy Markets
Governments worldwide are investing billions to revive a proven energy source. Supply chains are tightening, demand is rising, and select companies stand to benefit. The Nuclear’s Second Act report explains what’s happening next.
The Strategy
A bull call spread structured in October expiration fits this situation well. Buying the October 160 call and selling the October 175 call, for example, caps the premium at risk while leaving meaningful room for the stock to respond to favorable Phase 3 detail at ESMO. The spread profits if the market interprets the full INTerpath-001 numbers as confirmatory of the August headline. It loses only the premium paid if the data disappoint or arrive after expiration.
The critical risk is binary. Moderna and Merck have nine total Phase 2 and Phase 3 clinical trials underway for intismeran across multiple tumor types. The long-term platform is not in question at this congress. What is in question is whether the Phase 3 hazard ratio matches the 0.51 signal from Phase 2b, and whether overall survival trends are moving in the right direction. A weaker-than-expected hazard ratio or any new safety signal could send MRNA back toward the $120 range that followed the initial surge.
The Beast Verdict
Moderna has built a 137% month on data the market has not yet fully seen. ESMO on October 23 closes that gap. The opportunity here is not momentum chasing; it is positioning ahead of an event where the underlying science is strong, the catalyst is precisely dated, and implied volatility sits well below where it traded when the trade was most crowded. A defined-risk bull call spread in October expiration puts the ESMO thesis on with limited downside if the full INTerpath-001 readout falls short of what a 137% rally implies.
